Abstract Background Magnesium sulphate (MgSO 4) is the only treatment approved for fetal
neuroprotection. No information on its use is available in the absence of a national registry …

Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

This is a comment on" Antenatal magnesium sulphate for the prevention of cerebral palsy in
infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial." …

Importance Antenatal magnesium sulfate given to pregnant women at imminent risk of very
preterm delivery reduces the risk of cerebral palsy in early childhood, although its effects into …

Magnesium sulfate (MgSO 4) has been shown to prevent cerebral palsy among children
born to women at high risk of early preterm delivery. Three large, randomized placebo …

Society for Maternal-Fetal Medicine) have focused on the major obstetric controversy of
whether to use magnesium sulfate (MgSO4) in women likely to deliver preterm to prevent …

Cerebral lesions acquired in the perinatal period can induce cerebral palsy (CP), a
multifactorial pathology leading to lifelong motor and cognitive deficits. Several risk factors …

Objectives Although the benefit of magnesium sulfate to prevent cerebral palsy in antenatal
on very preterm infants has been shown, there is still reluctance to use it. The aim of this …

There is an important unmet need to improve long term outcomes of encephalopathy for
preterm and term infants. Meta-analyses of large controlled trials suggest that maternal …

Strategies for the prevention of cerebral palsy (CP) remain incompletely characterized.
Recognizing that half of all cases are associated with preterm delivery (Australian CP …